Richard L. Schilsky, MD, on Highlights of the 2016 ASCO Annual Meeting
2016 ASCO Annual MeetingRichard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.
Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.
Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.
Lisa A. Carey, MD, of the University of North Carolina, and Tuya Pal, MD, of H. Lee Moffitt Cancer Center & Research Institute, discuss the racial disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors (Abstract LBA1504).
Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses in Italian results from this phase III study of upfront autologous stem cell transplantation vs novel agent-based therapy for multiple myeloma (Abstract 8000).
Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).
Eric Roeland, MD, of the University of California, San Diego, and Timothy E. Quill, MD, of the University of Rochester Medical Center, discuss the debate on whether physician-assisted death should be a legally available option at the end of life when neither palliative nor hospice care is satisfactory.